The pharmacological modulation of PGC-1α regulates its downstream effectors, including COX6c, NRF-1, and TFAM, and might be a promising therapeutic tool to reduce oxidative stress-related clinical complications in ESRD/HD patients. Here, PPARGC1A is linked to Huntington disease.